Medical Education Grants Office (MEGO) Request for Proposal for an Independent Medical Education Grant
AstraZeneca's MEGO grant supports innovative education to improve multidisciplinary care and clinical expertise in TROP2-expressing NSCLC using the latest science and technology.
Funder: AstraZeneca United States
Due Dates: March 31, 2024 | October 1, 2026
Funding Amounts: No fixed minimum or maximum; funding is based on proposal scope and budget, subject to availability.
Summary: Supports independent medical education to advance multidisciplinary care and knowledge in TROP2-expressing Non-Small Cell Lung Cancer (NSCLC).
Key Information: Applications are reviewed on a rolling basis and funding is budget dependent.
Description
AstraZeneca United States, through its Medical Education Grants Office (MEGO), invites proposals for independent medical education grants focused on improving multidisciplinary team coordination in the diagnosis, treatment, and management of TROP2-expressing Non-Small Cell Lung Cancer (NSCLC). The program encourages innovative educational formats that integrate the latest clinical trial data, evidence-based guidelines, and emerging biomarkers, and build expertise in computational pathology, AI-assisted diagnostics, and test-to-treat decision-making. The goal is to enhance healthcare professionals’ understanding and application of new diagnostic and therapeutic approaches in thoracic immuno-oncology.
